Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit

AIDS

Volumn 18, Issue 10, 2004, Pages 1429-1433

  Casalino, Enrique ^a,b   Wolff, Michel ^a   Ravaud, Philippe ^a   Choquet, Christophe ^a   Bruneel, Fabrice ^a   Regnier, Bernard ^a  

^a BICHAT HOSPITAL   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

AIDS; Antiretroviral therapy; HIV; Intensive care; Pneumocystis carinii; Pneumonia; Prognosis; Sepsis; Survival; Toxoplasma

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SAMPLE SIZE; SCORING SYSTEM; SEPSIS; SURVIVAL RATE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 3142704155     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131301.55204.a7     Document Type: Article

References (27)

1. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999, 13: 415-418.
2. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 30 (Suppl 1):S5-S14.
3. Andrea Infuso, Françoise F. Hamers, Angela M. Downs, Jane Alix. La déclaration du VIH en Europe de l'ouest: Les systèmes nationaux et les premières données européennes. BEH 2000, 11.
4. Gulick R. Assessing the benefits of antiretroviral therapy. Ann Intern Med 2000, 133:471-473.
5. Afessa B, Green B. Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (Pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest 2000, 118:138-145.
6. Morris A, Wachter RM, Luce J, Turner J, Huang L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003, 17:73-80.
7. Morris A, Creasman J, Turner J, Luce JM, Wachter RM, Huang L. Intensive care of human immunodefiviency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med 2002, 166:262-267.
8. Casalino E, Mendoza-Sassi G, Wolff M, Bedos JP, Gaudebout C, Regnier B, et al. Predictors of short- and long-term survival in HIV-infected patients admitted to the ICU. Chest 1998, 113:421-429.
9. Gill JK, Greene L, Miller R, Pozniak A, Cartledge J, Fisher M, et al. ICU admission in patients infected with the human immunodeficiency virus - a multicentre survey. Anaesthesia 1999, 54:727-732.
10. De Palo VA, Millstein BH, Mayo PH, Salzman SH, Rosen MJ. Outcome of intensive care in patients with HIV infection. Chest 1995, 107:506-510.
11. Nickas G, Wachter RM. Outcomes of intensive care for patients with human immunodeficiency virus infection. Arch Intern Med 2000, 160:541-547.
12. Leifeld L, Rockstroh J, Skaide S, Wasmuth JC, Altfeld M, Paar WD, et al. Indication, outcome and follow up of intensive care in patients with HIV-infection. Eur J Med Res 2000, 5:199-202.
13. Bedos JP, Dumoulin JL, Gachot B, Veber B, Wolff M, Regnier B, et al. Pneumocystis carinii pneumonia requiring intensive care management: survival and prognostic study in 110 patients with human immunodeficiency virus. Crit Care Med 1999, 27: 1109-1115.
14. Rosen MJ, Clayton K, Schneider RF, Fulkerson W, Rao AV, Stansell J, et al. Intensive care of patients with HIV infection: utilization, critical illnesses, and outcomes. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997, 155:67-71.
15. Bedos JP, Chastang C, Lucet JC, Kalo T, Gachot B, Wolff M. Early predictors of outcome for HIV patients with neurological failure. JAMA 1995, 273:35-40.
16. Center for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 36 (suppl.):1S.
17. Le Gall JR, Lemeshow, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963.
18. Loirat P, Descamps JM, de Pouvourville G, et le Groupe d'étude multicentrique. Validation du système de mesure d'activité OMEGA. Rean Soins Intens Med Urg 1988, 4:387.
19. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining mortality among patients with advanced human immunodeficiency virus infection/HIV outpatient study investigators. N Engl J Med 1998, 338:853-860.
20. Detels R, Munoz A, McFarlane G, Kingsley L, Margolick J, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998, 280:1497-1503.
21. Jones JL, Hanson DL, Dworkin MS, Alderton D, Fleming P, Kaplan J, et al. Surveillance of AIDS-defining opportunistic illnesses, 1992-1997. MMWR Morb Mort Wkly Rep 1999, 48 (SS-2):1-22.
22. Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Resp Crit Care Med 2000, 162:64-67.
23. Jacobson MA, French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS 1998, S157-S163.
24. Selik RM, Chu SY, Ward JW. Trends in infectious diseases and cancer among persons dying of HIV infection in the United Sates from 1997 to 1992. Ann Intern Med 1995, 15:933-936.
25. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, Jones JL. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 30, Suppl 1:S5-S14.
26. Sansone GR, Frengley JD. Impact of HAART on causes of death of persons with late stage AIDS. J Urban Health 2000, 77: 166-175.
27. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001, 285:1308-1315.